Voloridge Investment Management
TBPH icon

Voloridge Investment Management’s Theravance Biopharma TBPH Stock Holding History

Voloridge Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,936
Closed -$173K – 1560
2023
Q1 		$173K Sell
15,936
-29,877
-65% -$316K ﹤0.01% 1319
2022
Q4 		$514K Buy
+45,813
New +$481K ﹤0.01% 1268
2022
Q3 		– Sell
-252,845
Closed -$2.29M – 1615
2022
Q2 		$2.29M Sell
252,845
-82,261
-25% -$758K 0.01% 974
2022
Q1 		$3.2M Buy
335,106
+161,036
+93% +$1.58M 0.02% 797
2021
Q4 		$1.92M Sell
174,070
-46,824
-21% -$408K 0.01% 1084
2021
Q3 		$1.64M Buy
+220,894
New +$2.47M 0.01% 1120
2020
Q4 		– Sell
-34,899
Closed -$516K – 1558
2020
Q3 		$516K Sell
34,899
-26,192
-43% -$491K ﹤0.01% 1081
2020
Q2 		$1.28M Buy
+61,091
New +$1.57M 0.01% 765
2020
Q1 		– Sell
-29,102
Closed -$753K – 1385
2019
Q4 		$753K Buy
+29,102
New +$566K 0.01% 723

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management's TBPH Position: Q2 2023 in Review

Voloridge Investment Management sold out of Theravance Biopharma (TBPH) in Q2 2023, closing a stake of 15,936 shares — an estimated $173K sold.

Voloridge Investment Management first reported a position in TBPH in Q4 2019 and held it in 9 quarters. The position peaked at $3.2M in Q1 2022. 119 funds tracked by Wall St. Rank hold TBPH as of Q2 2023.

  • Voloridge Investment Management reported no remaining Theravance Biopharma position as of Q2 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 15,936 Theravance Biopharma shares in Q2 2023, an estimated $173K.
  • Voloridge Investment Management first reported a position in Theravance Biopharma in Q4 2019 and held it in 9 quarters.
  • Voloridge Investment Management's Theravance Biopharma position peaked at $3.2M in Q1 2022.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2023.

Based on Voloridge Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.